MarketCapExport financials
Covetrus (CVET)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Covetrus Financial Ratios 2021-2011 | CVET
Brief overview of Covetrus's financial ratios
This overview follows the five latest available observations from 2017 through 2021.
The valuation comparison uses EV/EBITDA 28.17x (median 16.5x), P/S 0.54x (median 0.42x), P/B 1.61x (median 1.18x). The current ratio basket stands about 53.7% above the five-year base, increasing sensitivity to weak reports.
Capital efficiency is characterized by ROE -3.6%, ROA -1.6%, ROCE -1.5%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.
The cash conversion cycle lengthened from 28.1 days to 52.1 days, or 24 days. More cash is tied up in operations.
What the ratios show
Covetrus's profile looks stretched: price anticipates improvement that current quality ratios do not yet confirm.
Annual Financial Ratios Covetrus
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-45.8 | -211.6 | -1.3 | 14.8 | 23.3 | - | - | - | - | - | - |
P/S |
0.5 | 0.9 | 0.3 | 0.4 | 0.4 | - | - | - | - | - | - |
EPS |
-0.4 | -0.2 | -9.1 | 1.4 | 0.9 | - | - | - | - | - | - |
EV (Enterprise Value) |
4.17 B | 5.65 B | 3.28 B | 624 M | 939 M | 866 M | - | - | - | - | - |
EBITDA per Share |
1.08 | 0.83 | -7.88 | 2.83 | 2.73 | - | - | - | - | - | - |
EV/EBITDA |
28.2 | 57.7 | -3.9 | 3.1 | 4.8 | - | - | - | - | - | - |
PEG |
- | -2.13 | 0.0 | - | - | - | - | - | - | - | - |
P/B |
1.6 | 2.6 | 1.0 | 1.0 | 1.2 | - | - | - | - | - | - |
P/CF |
24.3 | 75.9 | 12.8 | 9.4 | 13.8 | - | - | - | - | - | - |
ROE % |
-3.57 | -1.24 | -78.21 | 6.96 | 5.27 | - | - | - | - | - | - |
ROA % |
-1.58 | -0.54 | -29.18 | 4.61 | 2.89 | - | - | - | - | - | - |
ROCE % |
-1.52 | -2.46 | -39.42 | 8.46 | 8.14 | - | - | - | - | - | - |
Current Ratio |
1.8 | 1.8 | 1.6 | 3.4 | 2.3 | - | - | - | - | - | - |
DSO |
39.4 | 39.2 | 39.3 | 20.8 | - | - | - | - | - | - | - |
DIO |
54.6 | 60.1 | 67.9 | 33.3 | - | - | - | - | - | - | - |
DPO |
41.9 | 48.0 | 54.3 | 26.0 | - | - | - | - | - | - | - |
Operating Cycle |
94.0 | 99.3 | 107.2 | 54.1 | - | - | - | - | - | - | - |
Cash Conversion Cycle |
52.1 | 51.4 | 52.9 | 28.1 | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Covetrus
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | -0.03 | -0.02 | - | -0.03 | -0.23 | -0.11 | -0.04 | -0.33 | 0.4 | -0.3 | -0.33 | -8.09 | -0.09 | -0.14 | 0.47 | 0.22 | 0.4 | 0.32 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | 0.32 | 0.33 | - | 0.28 | 0.25 | 0.29 | -0.14 | 0.12 | 0.33 | 0.18 | -0.22 | -8.19 | 0.32 | 0.27 | - | 0.7 | 0.76 | 0.67 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-0.66 | -0.66 | -2.73 | -3.51 | -3.38 | -3.64 | -5.85 | 0.45 | -1.25 | -3.94 | -69.64 | -74.31 | -72.14 | -66.91 | 2.33 | 4.72 | 6.83 | 1.07 | 1.94 | 1.54 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-0.29 | -0.29 | -1.20 | -1.55 | -1.49 | -1.60 | -2.48 | -0.05 | -0.53 | -1.51 | -27.74 | -29.51 | -28.87 | -26.26 | 1.68 | 3.22 | 4.55 | 0.72 | 1.30 | 1.03 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
0.39 | 0.39 | -0.21 | -0.67 | -1.06 | -2.30 | -3.94 | -3.65 | -5.12 | -5.88 | -76.06 | -75.97 | -74.69 | -70.43 | 3.94 | 6.70 | 9.24 | 2.28 | 2.55 | 2.14 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.5 | 1.6 | 1.7 | 2.2 | 2.2 | 3.4 | 3.5 | 3.5 | 3.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | 40.8 | 40.5 | - | 39.6 | 39.7 | 42.4 | 40.9 | 39.2 | 44.2 | 40.7 | 40.4 | 41.4 | 41.6 | 43.2 | 43.5 | 42.6 | 39.1 | 20.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | 56.2 | 60.0 | - | 53.5 | 52.4 | 55.5 | - | 49.4 | 57.8 | 63.9 | - | 64.1 | 64.9 | 69.4 | - | 68.0 | 62.6 | 33.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | 44.0 | 46.9 | - | 41.2 | 39.7 | 42.3 | - | 41.5 | 49.0 | 52.1 | - | 50.5 | 48.3 | 52.2 | - | 53.2 | 49.0 | 26.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | 100.4 | - | 93.1 | 92.1 | 97.9 | 41.3 | 90.5 | 102.9 | 103.8 | 38.6 | 108.4 | 109.7 | 113.2 | 43.5 | 110.6 | 101.7 | 54.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | 53.5 | - | 51.8 | 52.4 | 55.6 | 41.3 | 49.0 | 53.9 | 51.7 | 38.6 | 51.0 | 51.5 | 55.9 | 43.5 | 57.4 | 52.8 | 28.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Covetrus, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Veeva Systems
VEEV
|
$ 320.55 | 0.59 % | $ 52.5 B |  USA |
 |
Schrödinger
SDGR
|
$ 23.9 | 2.14 % | $ 1.76 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.34 | -4.96 % | $ 4.58 M |  China |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
HealthStream
HSTM
|
$ 33.51 | -0.77 % | $ 1.01 B | USA |
 |
Progyny
PGNY
|
$ 28.44 | -0.49 % | $ 2.42 B | USA |
 |
10x Genomics
TXG
|
$ 75.59 | 5.78 % | $ 9.43 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |
 |
American Well Corporation
AMWL
|
$ 13.97 | 5.91 % | $ 224 M | USA |
 |
Evolent Health
EVH
|
$ 4.83 | -0.82 % | $ 552 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Omnicell
OMCL
|
$ 36.34 | -0.41 % | $ 1.67 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.37 | 4.93 % | $ 174 M | USA |
 |
Phreesia
PHR
|
$ 12.26 | 1.78 % | $ 732 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.57 | 1.42 % | $ 1.27 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.74 | -0.57 % | $ 122 M | USA |
 |
So-Young International
SY
|
$ 2.19 | -3.1 % | $ 171 M | China |
 |
Teladoc Health
TDOC
|
$ 6.3 | 1.45 % | $ 1.11 B | USA |
 |
HealthEquity
HQY
|
$ 97.88 | 1.33 % | $ 8.43 B | USA |